Ki Y. Chung - Concepedia

Author

Ki Y. Chung

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Assunta De Rienzo, K. Chung, K. Y. CHUNG, K. Y. Chung, Ki Chung, Ki Y Chung, Ki Y. Chung, Ki Young Chung, Raphael Bueno

102

Publications

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Prisma Health The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute Istituti di Ricovero e Cura a Carattere Scientifico

About

Ki Y. Chung is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	3.5K
2	Health Sciences	8	8	2.8K
3	Cell Biology	3	3	202
4	Allergy	1	1	13
5	Allergy Medicine	1	1	13

Ki Y. Chung

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry Ki Y. Chung, Jinru Shia, Nancy E. Kemeny, Journal of Clinical Oncology	2005	1.1K
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, The Lancet Oncology OncologyGastrointestinal OncologyColorectal CancerPathologyCancer Treatment	2021	392
Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer Ki Y. Chung, Ira Gore, Lawrence Fong, Journal of Clinical Oncology	2010	303
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study Jinru Shia, David S. Klimstra, Allan R. Li, Modern Pathology Tumor BiologyGene AmplificationMedicineColorectal CancerPathology	2005	163
Constitutive Activation of STAT5A Promotes Human Hematopoietic Stem Cell Self-Renewal and Erythroid Differentiation Jan Jacob Schuringa, Ki Y. Chung, Giovanni Morrone, The Journal of Experimental Medicine Developmental BiologyConstitutive ActivationMedicineStem Cell MobilizationHematology	2004	135
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Clinical Cancer Research	2021	135
Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of <i>WT p53</i> in patients with solid tumors and lymphomas. Funda Meric‐Bernstam, Mansoor N. Saleh, Jeffrey R. Infante, Journal of Clinical Oncology Tp53 Wild-typeSolid TumorsImmunologyPathologyPeptide Science	2017	78
Enforced Expression of <i>NUP98-HOXA9</i> in Human CD34+ Cells Enhances Stem Cell Proliferation Ki Y. Chung, Giovanni Morrone, Jan Jacob Schuringa, Cancer Research	2006	75
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors Jason J. Luke, Fabrice Barlési, Ki Y. Chung, Journal for ImmunoTherapy of Cancer	2021	58

Page 1